201 related articles for article (PubMed ID: 15072617)
1. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma.
Arcaini L; Orlandi E; Scotti M; Brusamolino E; Passamonti F; Burcheri S; Colombo N; Vanelli L; Sbalzarini G; Lazzarino M
Clin Lymphoma; 2004 Mar; 4(4):250-2. PubMed ID: 15072617
[TBL] [Abstract][Full Text] [Related]
2. Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases.
Wöhrer S; Troch M; Zwerina J; Schett G; Skrabs C; Gaiger A; Jaeger U; Zielinski CC; Raderer M
Ann Oncol; 2007 Apr; 18(4):647-51. PubMed ID: 17218490
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Yoon DH; Yang DH; Lee WS; Kim HJ; Yhim HY; Jeong SH; Won JH; Lee S; Kong JH; Lim SN; Ji JH; Kwon KA; Lee GW; Lee JH; Lee HS; Shin HJ; Suh C
Cancer Commun (Lond); 2019 Oct; 39(1):58. PubMed ID: 31619290
[TBL] [Abstract][Full Text] [Related]
4. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients.
Thieblemont C; Felman P; Berger F; Dumontet C; Arnaud P; Hequet O; Arcache J; Callet-Bauchu E; Salles G; Coiffier B
Clin Lymphoma; 2002 Jun; 3(1):41-7. PubMed ID: 12141954
[TBL] [Abstract][Full Text] [Related]
5. Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study.
Iannitto E; Luminari S; Tripodo C; Mancuso S; Cesaretti M; Marcheselli L; Merli F; Stelitano C; Carella AM; Fragasso A; Montechiarello E; Ricciuti G; Pulsoni A; Paulli M; Franco V; Federico M
Leuk Lymphoma; 2015; 56(12):3281-7. PubMed ID: 25791121
[TBL] [Abstract][Full Text] [Related]
6. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study.
Jäeger G; Neumeister P; Brezinschek R; Höfler G; Quehenberger F; Linkesch W; Sill H
Eur J Haematol; 2002 Jul; 69(1):21-6. PubMed ID: 12270058
[TBL] [Abstract][Full Text] [Related]
7. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
8. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
9. Rituximab-CHOP or two-weekly CHOP + G-CSF in aggressive lymphoma of the elderly?
Todeschini G; Gelio S; Tecchio C
Ann Oncol; 2004 Mar; 15(3):538-9. PubMed ID: 14998863
[No Abstract] [Full Text] [Related]
10. Aggressive lymphoma: improving treatment outcome with rituximab.
Coiffier B; Pfreundschuh M; Stahel R; Vose J; Zinzani PL
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S43-50. PubMed ID: 12710590
[TBL] [Abstract][Full Text] [Related]
11. Rituximab-CHOP or 2-weekly CHOP + G-CSF in aggressive lymphoma of the elderly?
Bernardi D; Giacalone A; Spina M; Tirelli U
Ann Oncol; 2004 Aug; 15(8):1298. PubMed ID: 15277275
[No Abstract] [Full Text] [Related]
12. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
13. Immunochemotherapy in indolent non-Hodgkin's lymphoma.
Czuczman MS
Semin Oncol; 2002 Apr; 29(2 Suppl 6):11-7. PubMed ID: 12040529
[TBL] [Abstract][Full Text] [Related]
14. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
Raderer M; Wohrer S; Streubel B; Drach J; Jager U; Turetschek K; Troch M; Puspok A; Zielinski CC; Chott A
Oncology; 2006; 70(6):411-7. PubMed ID: 17220639
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Gilman P; Lowe A; Kunkel LA; Fisher RI
J Clin Oncol; 2001 Jan; 19(2):389-97. PubMed ID: 11208830
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
17. T-cell-rich B-cell lymphoma of the spleen presenting with severe hypersplenism.
Dincol G; Agan M; Dogan O; Diz-Kucukkaya R; Uslu B
Clin Lab Haematol; 2006 Dec; 28(6):419-22. PubMed ID: 17105497
[TBL] [Abstract][Full Text] [Related]
18. Rituximab plus CHOP as an initial chemotherapy for patients with disseminated MALT lymphoma.
Ennishi D; Yokoyama M; Mishima Y; Watanabe C; Terui Y; Takahashi S; Takeuchi K; Ikeda K; Tanimoto M; Hatake K
Leuk Lymphoma; 2007 Nov; 48(11):2241-3. PubMed ID: 17990181
[No Abstract] [Full Text] [Related]
19. The treatment of lymphoma complicating autoimmune disease: two birds with one stone?
Mikuls TR
Ann Oncol; 2007 Apr; 18(4):615-8. PubMed ID: 17355949
[No Abstract] [Full Text] [Related]
20. Intravascular lymphoma presenting with cauda equina syndrome: treated with CHOP and rituxan.
Davis TS
Leuk Lymphoma; 2003 May; 44(5):887-8. PubMed ID: 12802932
[No Abstract] [Full Text] [Related]
[Next] [New Search]